Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Uterine sarcoma: a retrospective study.

B C Wen, F A Tewfik, H H Tewfik

    Journal of Surgical Oncology
    |February 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Counselling for alcohol problems in primary care in Forth Valley--an innovative approach?

    Health bulletin·2003
    Same author

    Responsiveness of the Problem Areas In Diabetes (PAID) questionnaire.

    Diabetic medicine : a journal of the British Diabetic Association·2003
    Same author

    Vagus nerve stimulation therapy: a research update.

    Neurology·2002
    Same author

    Funding cuts compromise sexual health care.

    Nursing New Zealand (Wellington, N.Z. : 1995)·2002
    Same author

    Nursing service adapts to changing needs and funding.

    Nursing New Zealand (Wellington, N.Z. : 1995)·2002
    Same author

    The public perceptions of the rewards and risks of genetic research: the Oregon story.

    Professional ethics report : newsletter of the American Association for the Advancement of Science, Committee on Scientific Freedom & Responsibility, Professional Society Ethics Group·2002

    Treatment outcomes for uterine sarcoma show that surgery alone has a 40% disease-free survival. Combining surgery with chemotherapy or radiation therapy offers modest improvements but no statistical significance, with tumor extent being key.

    Area of Science:

    • Gynecology
    • Oncology
    • Surgical Oncology

    Background:

    • Uterine sarcoma is a rare malignancy.
    • Optimal treatment strategies remain under investigation.
    • Understanding prognostic factors is crucial for patient management.

    Purpose of the Study:

    • To evaluate the efficacy of different treatment modalities for uterine sarcoma.
    • To identify prognostic factors influencing disease-free survival and local failure.
    • To analyze treatment outcomes in a historical cohort.

    Main Methods:

    • Retrospective analysis of 86 patients with uterine sarcoma treated between 1965 and 1982.
    • Categorization of patients based on disease stage (curable vs. advanced).
    • Comparison of disease-free survival and local failure rates across treatment groups: surgery only, surgery + chemotherapy, and surgery + radiation +/- chemotherapy.

    Related Experiment Videos

    Main Results:

    • For patients with curable disease (n=67), 5-year disease-free survival rates were 40% (surgery only), 53% (surgery + chemotherapy), and 46% (surgery + radiation +/- chemotherapy).
    • Local failure rates were 43% (surgery only), 32% (surgery + chemotherapy), and 33% (surgery + radiation +/- chemotherapy).
    • No statistically significant differences were observed between treatment groups; clinical tumor extent was the most significant prognostic factor.

    Conclusions:

    • While adjuvant therapies like chemotherapy and radiation may offer a trend towards improved outcomes, they did not reach statistical significance in this cohort.
    • The clinical extent of the uterine sarcoma is the primary determinant of prognosis.
    • Further research may be warranted to define the precise role of chemotherapy and radiation in uterine sarcoma management.